Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2023

The Pharma Closeout tracks 284 deals, $232.8B in disclosed deal value, 33 with a post-close Outcome Score for the year 2023.

Median Critic Score: 83  ·  Median Outcome Score: 69

Best outcome: Summit Therapeutics plc / Akeso Inc. (79)  ·  Weakest outcome: Novo Nordisk A/S / KBP Biosciences (26)

All 284 deals

• Summit Therapeutics plc / Akeso Inc. — 2023 · $4.5B · Worked — the deal delivered on its rationale.
• Novartis AG / Chinook Therapeutics Inc. — 2023 · $3.5B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / CinCor Pharma Inc. — 2023 · $1.8B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Prometheus Biosciences Inc. — 2023 · $10.8B · Worked — the deal delivered on its rationale.
• Danaher Corporation / Abcam PLC — 2023 · $5.7B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Seagen Inc. — 2023 · $43.0B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Karuna Therapeutics — 2023 · $14.0B · Worked — the deal delivered on its rationale.
• GSK plc / Hansoh Pharmaceutical Group Co. Ltd. — 2023 · $1.7B · Largely worked — most objectives met.
• Biogen Inc. / Reata Pharmaceuticals — 2023 · $7.3B · Largely worked — most objectives met.
• Roche Holding AG / Telavant Holdings — 2023 · $7.1B · Largely worked — most objectives met.
• Roche Holding AG / Alnylam Pharmaceuticals Inc. — 2023 · $2.8B · Largely worked — most objectives met.
• Chiesi Farmaceutici S.p.A. / Amryt Pharma plc — 2023 · $1.5B · Largely worked — most objectives met.
• Roche Holding AG / Carmot Therapeutics Inc. — 2023 · $2.7B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / SystImmune Inc. — 2023 · $8.4B · Largely worked — most objectives met.
• Sanofi SA / Provention Bio Inc. — 2023 · $2.9B · Largely worked — most objectives met.
• Novartis AG / Legend Biotech Corporation — 2023 · $1.1B · Largely worked — most objectives met.
• AbbVie Inc. / ImmunoGen Inc. — 2023 · $10.1B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / RayzeBio Inc. — 2023 · $4.1B · Largely worked — most objectives met.
• Merck & Co. Inc. / Daiichi Sankyo Company, Limited — 2023 · $22.0B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Mirati Therapeutics — 2023 · $4.8B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Evotec SE — 2023 · $4.0B · Largely worked — most objectives met.
• AstraZeneca PLC / Gracell Biotechnologies — 2023 · $1.2B · Largely worked — most objectives met.
• Eli Lilly and Company / Versanis Bio — 2023 · $1.9B · Largely worked — most objectives met.
• Merck & Co. Inc. / Proxygen GmbH — 2023 · $2.5B · Largely worked — most objectives met.
• Eli Lilly and Company / Point Biopharma — 2023 · $1.4B · Largely worked — most objectives met.
• Novo Nordisk A/S / Inversago Pharma — 2023 · $1.1B · Largely worked — most objectives met.
• AstraZeneca PLC / Icosavax Inc. — 2023 · $1.1B · Largely worked — most objectives met.
• Swedish Orphan Biovitrum AB / CTI BioPharma Corp. — 2023 · $1.7B · Largely worked — most objectives met.
• AstraZeneca PLC / Absci Corporation — 2023 · $247M · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / DICE Therapeutics Inc. — 2023 · $2.4B · Mixed — partial payoff, real shortfalls.
• Immunome Inc. / Morphimmune Inc. — 2023 · $125M · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Cerevel Therapeutics — 2023 · $8.7B · Underwhelmed — fell short of the thesis.
• Novo Nordisk A/S / KBP Biosciences — 2023 · $1.3B · Did not work — the deal failed to deliver.
• Astellas / Sony — 2023
• Palisade Bio / Giiant Pharma, Inc. — 2023
• Hummingbird Bioscience / Synaffix — 2023
• ImaginAb / Quibim — 2023
• Leap Therapeutics / Flame Biosciences — 2023
• OncoHost / BGN Technologies — 2023
• First Wave BioPharma, Inc. / Sanofi — 2023
• Ginkgo Bioworks / Esperovax — 2023
• Ginkgo Bioworks / Prokarium — 2023
• Hillstream BioPharma / Applied Biomedical Science Institute (ABSI) — 2023
• AstraZeneca PLC / Quell Therapeutics Limited — 2023 · $2.1B
• Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG — 2023 · $330M
• Almirall / Absci — 2023
• FibroGen / Fortis Therapeutics — 2023
• Novo Nordisk / Embark Biotech — 2023
• Boehringer Ingelheim International GmbH / T3 Pharmaceuticals AG — 2023 · $508M
• AbbVie / Anima Biotech — 2023
• Merck & Co. Inc. / Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — 2023 · $9.5B
• Chinook Therapeutics / Ionis — 2023
• Annji Pharmaceutical / Avenue Therapeutics — 2023
• GSK / WuXi Biologics — 2023
• Bridge Biotherapeutics / GPCR Therapeutics — 2023
• Concentra Biosciences / Theseus Pharmaceuticals — 2023
• Dynacare / Valley Medical Laboratories — 2023
• Dignify Therapeutics / Aayam Therapeutics — 2023
• AmMax Bio / Evopoint Biosciences — 2023
• Moderna / CytomX — 2023
• Predictive Oncology / Cvergenx — 2023
• Ayala Pharmaceuticals / Biosight — 2023
• Kaken Pharmaceutical Co., Ltd. / CymaBay Therapeutics — 2023
• Eyenovia / Formosa Pharmaceuticals — 2023
• InnoCare / ArriVent — 2023
• Aju Pharm Co., Ltd. / Stuart Therapeutics, Inc. — 2023
• Ono / Adimab — 2023
• Catamaran Bio / MaxCyte — 2023
• 4D Molecular Therapeutics / Aevitas Therapeutics — 2023
• Torii Pharmaceutical / Nogra Pharma — 2023
• Sanofi SA / BioMap Holdings Limited — 2023 · $1.0B
• AbbVie Inc. / Mitokinin, Inc. — 2023 · $655M
• Century Therapeutics / FUJIFILM Cellular Dynamics — 2023
• Pharmazz, Inc. / Sun Pharma — 2023
• Celltrion / Liscure Biosciences — 2023
• Adamis Pharmaceuticals / DMK Pharmaceuticals — 2023
• Novo Nordisk / Genevant Sciences — 2023
• Exelixis / Ajinomoto — 2023
• uniQure / Apic Bio — 2023
• Merck / Aqilion — 2023
• Mainz Biomed / Microba Life Sciences — 2023
• Bristol Myers Squibb / Karyopharm — 2023
• Daewoong Pharmaceutical / Oncorus — 2023
• Dianthus Therapeutics / Magenta Therapeutics — 2023
• Yuhan Corporation / J Ints Bio — 2023
• Neurosense / Quantalx — 2023
• BioCryst / Clearside Biomedical — 2023
• Baylor BioSciences / Bellerophon Therapeutics — 2023
• BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. — 2023 · $1.7B
• Coherus / Surface Oncology — 2023
• Takeda Pharmaceutical Company Ltd. / HUTCHMED (China) Limited — 2023 · $1.1B
• Mother’s Pharmaceutical / Triple Hair Group — 2023
• Genmab / argenx — 2023
• Shoreline Biosciences / Editas Medicine — 2023
• Caris Life Sciences / ConcertAI — 2023
• VivaVision / Everads — 2023
• Bavarian Nordic / Emergent BioSolutions — 2023 · $380M
• Zymo Research / Opentrons — 2023
• UCB / Ariceum Therapeutics — 2023
• GeoVax Labs, Inc. / ProBioGen — 2023
• F. Hoffmann-La Roche AG / Ionis Pharmaceuticals, Inc. — 2023 · $760M
• Pacbio / Apton Biosystems — 2023 · $110M
• Gritstone bio / Genevant Sciences — 2023
• Janssen / Cellular Biomedicine Group — 2023
• BioNTech / InstaDeep — 2023
• Pierre Fabre Laboratories / Vernalis — 2023
• MSD / Wellmarker Bio — 2023
• SERB Pharmaceuticals / Wellstat Therapeutics — 2023
• Prelude Therapeutics / AbCellera — 2023
• eGenesis / Eledon Pharmaceuticals — 2023
• Zenyaku Kogyo / ASLAN Pharmaceuticals — 2023
• Factorial Biotechnologies / Watchmaker Genomics — 2023
• Merck & Co. Inc. / ImmunOs Therapeutics — 2023
• Ers Genomics / Transomic Technologies — 2023
• ABVC BioPharma / MerDury BioPharma — 2023
• Amgen / TScan Therapeutics — 2023
• Servier / QIAGEN — 2023
• Ordaōs / FatiAbGen — 2023
• Seagen / Nurix — 2023
• LegoChem Biosciences / Glycotope — 2023
• AbbVie / Immunome — 2023
• Ethris / Heqet Therapeutics — 2023
• Rakuten Medical / Hikma — 2023
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. / Sanyou Biopharmaceuticals Co., Ltd. — 2023
• VBL Therapeutics / Notable Labs — 2023
• AskBio / ReCode Therapeutics — 2023
• Blue Water Vaccines / AbVacc — 2023
• Vittoria Biotherapeutics / MaxCyte — 2023
• Ono Pharmaceutical / Cue Biopharma — 2023
• Ovid Therapeutics / Graviton Bioscience — 2023
• POINT Biopharma Global Inc. / Athebio — 2023
• Clexio / Genetika+ — 2023
• Tonix Pharmaceuticals Holding Corp. / Upsher-Smith Laboratories, LLC — 2023
• Phanes Therapeutics / Xyphos Biosciences Inc — 2023
• AstraZeneca PLC / LaNova Medicines Ltd. — 2023 · $600M
• InxMed / Escugen — 2023
• Royalty Pharma / Ionis — 2023 · $1.1B
• Gilead / Compugen — 2023
• Assertio Holdings, Inc. / Spectrum Pharmaceuticals, Inc. — 2023 · $291M
• Orion / Amneal — 2023
• Sun Pharma / Concert Pharmaceuticals — 2023 · $576M
• Kriya / Tramontane Therapeutics — 2023
• Bliss Biopharmaceutical / Eisai — 2023
• Roche / Monte Rosa Therapeutics — 2023
• Atavistik Bio / Plex Research — 2023
• Boehringer Ingelheim International GmbH / Ginkgo Bioworks Holdings, Inc. — 2023 · $405M
• Zai Lab / Medilink Therapeutics — 2023
• Takeda / F-star Therapeutics, Inc. — 2023
• Araris Biotech AG / ARS Pharmaceutical — 2023
• Defender Pharmaceuticals / U.S. Army Medical Materiel Development Activity — 2023
• Novartis AG / Voyager Therapeutics Inc. — 2023 · $1.3B
• Acumen Pharmaceuticals, Inc. / Halozyme — 2023
• Bj Bioscience / MSD — 2023
• Aligos Therapeutics / Xiamen Amoytop Biotech Co., Ltd. — 2023
• Revolution Medicines, Inc. / EQRx, Inc. — 2023
• Aspira Women’s Health / Dana-Farber Cancer Institute — 2023
• Cure Genetics / Frametact — 2023
• Absci / M2GEN — 2023
• Sun Pharma / Aclaris Therapeutics — 2023
• Sumitomo Pharma / Salipro Biotech — 2023
• Invitae / Deerfield Management — 2023
• LEO Pharma A/S / Timber Pharmaceuticals, Inc. — 2023 · $36M
• AstraZeneca PLC / Cellectis SA — 2023 · $605M
• Axcelead Drug Discovery Partners (DDP) / ThinkCyte — 2023
• Novo Nordisk A/S / Omega Therapeutics, Inc. — 2023
• Day One Biopharmaceuticals Inc. / Sprint Bioscience — 2023
• Hasten Biopharmaceutic Co., Ltd (China) / Roche — 2023
• Verismo Therapeutics / University of Pennsylvania — 2023
• Talaris Therapeutics / Tourmaline Bio — 2023
• Absci / PrecisionLife — 2023
• Searchlight Pharma / Sol-Gel — 2023
• Merck / Nectin Therapeutics — 2023
• Factorial Biotechnologies / Ginkgo Bioworks — 2023
• M8 Pharmaceuticals / Daewoong Pharmaceuticals — 2023
• Harmony Biosciences / Zynerba Pharmaceuticals Inc — 2023 · $200M
• Elicio Therapeutics / Angion — 2023
• Alexion / Verge Genomics — 2023
• CohBar, Inc. / Morphogenesis, Inc. — 2023
• GreenLight Biosciences / Epivax Therapeutics — 2023
• Aardvark Therapeutics, Inc. / GRI Bio, Inc. — 2023
• Revive Therapeutics / PharmaTher — 2023
• Bill & Melinda Gates Medical Research Institute / Calibr — 2023
• Amgen / Synaffix — 2023
• Flamingo Therapeutics / Dynacure — 2023
• Mirus Bio / Kytopen — 2023
• Eli Lilly and Company / Beam Therapeutics Inc. — 2023 · $600M
• Adenomed / Purnovate, Inc. — 2023
• Neurocrine Biosciences / Voyager Therapeutics — 2023
• Maruho Co., Ltd. / Journey Medical Corporation — 2023
• Bristol-Myers Squibb Company / Tubulis GmbH — 2023 · $1.0B
• Gc Biopharma / Catalyst Biosciences — 2023
• Novo Nordisk / Life Edit Therapeutics — 2023
• NAYA Biosciences / ONK Therapeutics — 2023
• Viatris Pharmaceutical Japan Inc. / Index Pharmaceuticals — 2023
• Kriya Therapeutics, Inc. / Everads Therapy, Ltd — 2023
• Eli Lilly and Company / PRISM BioLab — 2023
• Taiho Pharmaceutical / Araris Biotech AG — 2023
• Orion Corporation / Proteros biostructures — 2023
• Cabaletta Bio / Autolus Therapeutics — 2023
• Third Rock Ventures / Deep Forest Sciences — 2023
• BullFrog AI / Johns Hopkins University — 2023
• Eterna Therapeutics / Exacis Biotherapeutics — 2023
• Ray Therapeutics Inc. / Adverum Biotechnologies — 2023
• Sanofi SA / Maze Therapeutics, Inc. — 2023 · $750M
• Nona Biosciences / Mythic Therapeutics — 2023
• Sanofi / Recludix Pharma — 2023
• Merck / Hummingbird Bioscience — 2023
• AstraZeneca PLC / Eccogene (Shanghai) Co., Ltd. — 2023 · $2.0B
• GSK plc / SCYNEXIS, Inc. — 2023 · $593M
• Phoenixus AG / Vyera Pharmaceuticals, LLC — 2023
• OPKO Biologics / Entera Bio — 2023
• Ers Genomics / Santa Cruz Biotechnology — 2023
• Eli Lilly and Company / Sigilon Therapeutics Inc. — 2023 · $310M
• Renaissance Pharma / St. Jude Children’s Research Hospital — 2023
• Immunobiochem / Immunogen — 2023
• Amolyt Pharma / XOMA — 2023
• United Therapeutics / Miromatrix Medical — 2023 · $91M
• Teijin Limited / Ascendis Pharma — 2023
• Catalyst Pharmaceuticals / Santhera Pharmaceuticals — 2023
• Everest Medicines / Kezar Life Sciences — 2023
• Genentech / Kronos Bio — 2023
• Ironwood Pharmaceuticals, Inc. / VectivBio Holding AG — 2023 · $1.0B
• Knight Therapeutics / Supernus Pharmaceuticals — 2023
• Evaxion / Afrigen Biologics — 2023
• Biosynex / Chembio Diagnostics — 2023 · $17M
• Pathos AI / Rain Oncology — 2023
• Syncona / Freeline Therapeutics — 2023
• Lotus Pharmaceuticals / NRx Pharmaceuticals — 2023
• Neuro3 Therapeutics / Lundbeck — 2023
• Innovent / Sanegenebio — 2023
• AcuraStem / Takeda — 2023 · $580M
• Traverse Biotech / Genmab — 2023
• BioNTech / DualityBio — 2023
• Inhibrx / NorthStar Medical Radioisotopes — 2023
• Cullinan Oncology / Harbour BioMed — 2023
• ALX Oncology / Sanofi — 2023
• Sanofi SA / Teva Pharmaceutical Industries Ltd. — 2023 · $1.5B
• GSK plc / Bellus Health Inc. — 2023 · $2.0B
• MiNK Therapeutics / ImmunoScape — 2023
• Vertex / Stablix — 2023
• QIAGEN / Helix — 2023
• Simcere / Connect Biopharma — 2023
• Takeda / Adaptive Biotechnologies — 2023
• Regeneron / Decibel Therapeutics — 2023 · $213M
• Solid Biosciences / Phlox Therapeutics — 2023
• GeneQuantum / BioMap — 2023
• Novo Nordisk / Dewpoint Therapeutics — 2023
• Avanzanite Bioscience / SIFI — 2023
• Clearmind Medicine / CTS Ltd. — 2023
• GENFIT / Seal Rock Therapeutics — 2023
• Eli Lilly and Company / XtalPi — 2023 · $250M
• Eli Lilly and Company / Mablink Bioscience SAS — 2023 · $250M
• Bristol Myers Squibb / Zenas BioPharma — 2023
• Novo Nordisk A/S / Aspect Biosystems Ltd. — 2023 · $2.7B
• Sobi / CTI BioPharma Corp. — 2023 · $1.7B
• Betta Pharmaceuticals / C4 Therapeutics — 2023
• Ultima Genomics / 10x Genomics — 2023
• SomaLogic / Dante Genomics — 2023
• Prime Medicine / Cimeio Therapeutics — 2023
• Celest Therapeutics / Senti Bio — 2023
• Pfizer Inc. / Nona Biosciences (Harbour BioMed subsidiary) — 2023 · $1.1B
• Spark Therapeutics / Neurochase — 2023
• Incyte / Caris Life Sciences — 2023
• MaxCyte / Prime Medicine — 2023
• Fosun Pharma / Henlius — 2023
• Merck KGaA, Darmstadt, Germany / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2023
• Jacobio / Merck & Co., Inc., Rahway, NJ, USA — 2023
• Blacksmith Medicines / Forge Therapeutics — 2023
• Celloram Inc / GENFIT — 2023
• Zoetis / EpiVax — 2023
• Sanofi SA / Janssen Pharmaceuticals, Inc. (Johnson & Johnson) — 2023 · $175M
• Pyxis Oncology / Apexigen — 2023 · $16M
• AbbVie Inc. / Aldeyra Therapeutics, Inc. — 2023 · $400M
• Baxter / Miromatrix — 2023
• Novo Nordisk A/S / Valo Health, Inc. — 2023 · $4.8B
• AstraZeneca / Sernova — 2023
• Vertex Pharmaceuticals / Editas Medicine — 2023
• SNBL / Satsuma Pharmaceuticals — 2023
• Walking Fish Therapeutics / MaxCyte — 2023
• Simnova / Orna Therapeutics — 2023
• Eli Lilly and Company / Capsida Biotherapeutics — 2023
• Rona Therapeutics / Keymed Biosciences — 2023
• Lilly / Sitryx — 2023
• Cantex Pharmaceuticals / Georgetown University — 2023

← Deal Library  ·  Interactive search  ·  How we score deals